<< Back to News

New FDA Approval for GAZYVA®

GAZYVA® obinutuzumab) is NOW FDA APPROVED for use in combination with bendamustine followed by GAZYVA monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.

Click Here for the Prescribing Information.

Click Here for coding and other information. 

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.